W2J Stock Overview
A clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Carisma Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$6.30 |
| 52 Week Low | US$0.71 |
| Beta | 0 |
| 11 Month Change | -5.28% |
| 3 Month Change | -23.88% |
| 1 Year Change | -82.39% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 67.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| W2J | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 19.7% | -0.6% | 3.3% |
| 1Y | -82.4% | -22.0% | 4.7% |
Return vs Industry: W2J underperformed the German Biotechs industry which returned -22% over the past year.
Return vs Market: W2J underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| W2J volatility | |
|---|---|
| W2J Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: W2J's share price has been volatile over the past 3 months.
Volatility Over Time: W2J's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 107 | Steve Kelly | www.carismatx.com |
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.
Carisma Therapeutics, Inc. Fundamentals Summary
| W2J fundamental statistics | |
|---|---|
| Market cap | €42.37m |
| Earnings (TTM) | -€65.43m |
| Revenue (TTM) | €18.69m |
2.3x
P/S Ratio-0.6x
P/E RatioIs W2J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| W2J income statement (TTM) | |
|---|---|
| Revenue | US$20.71m |
| Cost of Revenue | US$71.74m |
| Gross Profit | -US$51.02m |
| Other Expenses | US$21.48m |
| Earnings | -US$72.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.75 |
| Gross Margin | -246.38% |
| Net Profit Margin | -350.08% |
| Debt/Equity Ratio | 0% |
How did W2J perform over the long term?
See historical performance and comparison